Biopharma Market to Grow $546.6 Billion by 2027: at 10.6% CAGR

ReportCrux Market Research has published a new report titled “Biopharma Market by Product (Monoclonal Antibodies [Anti Cancer Monoclonal Antibodies, Anti Inflammatory Monoclonal Antibodies, and Other Monoclonal Antibodies], Purified Proteins [Leukemia Inhibitory Factor (LIF), P53 Protein, P38 Protein, and Other Purified Proteins], Recombinant Proteins [Serum Albumin, Amyloid Protein, Defensin, and Transferrin], Vaccines [Recombinant Vaccines, Conventional Vaccines, and Recombinant Enzymes], Recombinant Growth Factors [Erythropoietin, and Granulocyte Colony Stimulating Factors], Recombinant Hormones [Recombinant Human Growth Hormones, Recombinant Insulin, and Other Recombinant Hormones], and Other Product Types); by Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Hormonal Disorders, and Other Diseases); and by Region: Global Industry Trends, Dynamics, Competitive Insights and Forecast Analysis, 2020 – 2027”.

Get a Sample Copy of the Report – https://www.reportcrux.com/request-sample-report/Biopharma-Market

Market Size 2019-2027:

Global demand for biopharma market was valued at approximately USD 244.1 Billion in 2019 and is expected to generate revenue of around USD 546.6 Billion by end of 2027, growing at a CAGR of around 10.6% between 2020 and 2027.

Market Analysis and Overview: Global Biopharma Market

Biopharmaceuticals are produced by living organisms, such as microorganisms and animal cells, and have a high therapeutic value. Most biopharmaceuticals are life-form pharmaceutical products, genetically modified from plants and animals and are classified as transgenic organisms, and this process is used to generate biopharmaceuticals. These massive and complex molecular drugs are often referred to as biologics or biotech drugs. Recombinant human insulin was one of the first substances to be licensed for medical purposes, and there are currently almost 300 biopharmaceutical drugs that have been licensed and are available on the market.

The global demand for biopharmaceuticals is driven by a number of factors like increase in the elderly population, an increase in the prevalence of chronic diseases like cancer and diabetes, and an increase in the global acceptance of biopharmaceuticals. In addition, an increase in strategic partnerships between biopharmaceutical companies is also expected to complement the growth of the biopharmaceuticals industry. Furthermore, clearance for newer biopharmaceutical products and continuous R&D is also expected to improve this market positively. However, the high costs of these medications are one of the main constraints on this industry and, in order to make them economically viable, the cost needs to be reduced greatly.

Regional and Country-level Analysis

Regionally, the market is divided into Asia Pacific, Europe, Latin America, North America, and Middle East & Africa. North America held almost 37% in 2019 due to the presence of sophisticated healthcare facilities, increasing geriatric population base, and increased healthcare expenditure in the country. Asia Pacific is likely to grow at high CAGR in the forecast period. Increased investment in R&D, increased acceptance and availability of biopharmaceuticals for disease treatment and increased understanding of disease diagnosis are some of the factors of market growth in this region. Moreover, this area offers tremendous prospects for venture capitalists and investors as developed markets are largely saturated.

Segmentation Analysis:

The global market for the biopharma is segmented into product, therapeutic area, application, and region. Based on product, the market is for biopharma is segmented into recombinant growth factors, monoclonal antibodies, recombinant proteins, vaccines, purified proteins, recombinant hormones, and other product types. The monoclonal antibodies market is further divided into anti-inflammatory monoclonal antibodies, anti-cancer monoclonal antibodies, and other monoclonal antibodies. The purified proteins market is further bifurcated into P38 protein, leukemia inhibitory factor, P53 protein, and other purified proteins. The recombinant proteins market is further divided into serum albumin, defensin, amyloid protein, and transferrin. Vaccines are further divided into conventional vaccines, recombinant vaccines, and recombinant enzymes. The recombinant growth factors are further divided into granulocyte colony stimulating factors, and erythropoietin. The recombinant hormones market is further divided into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The market for monoclonal antibodies held almost 28% share of the market in 2019. Monoclonal antibodies are used in cancer treatment areas. Their usage is becoming increasingly widespread in developed countries like the U.S. and the U.K. Contrary, the recombinant proteins segment is expected to show rapid growth over the forecast period.

Based on therapeutic application, the market is categorized into oncology, inflammatory and infectious diseases, neurological diseases, infectious diseases, cardiovascular diseases, metabolic disorders, hormonal disorders, and other diseases. The oncology segment held almost 25% share of the market in 2019. According to the International Agency for Cancer Research (IARC), there were almost 18 million new cases of cancer and 10 million deaths in 2018. In fact, the United Nations Program on HIV and AIDS (UNAIDS) estimated that 37 million people were living with HIV in 2017. Such disquieting statistics has raised an urgent need to change the situation by innovating new and successful medicines that can cure such deadly diseases consequently raising the number of deaths. Apparently, biopharmaceutical drugs are considered to be effective in curing these chronic diseases rather than merely treating the same symptoms.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT on Biopharma Market

Major Key Players of 2020 Biopharma Market Report:

Major players in biopharma market are Novo Nordisk A/S (Denmark), Johnson & Johnson (U.S.), Pfizer, Inc., (U.S.), Hoffmann-La Roche (Switzerland), Eli Lilly and Company, Ltd. (U.K.), Biogen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Bristol Myers Squibb Company (U.S.), and Bayer AG (Germany) among others.

The report segments of global Biopharma market are as follows:

By Product

• Monoclonal Antibodies

• • Anti Cancer Monoclonal Antibodies

  • Anti Inflammatory Monoclonal Antibodies

  • Other Monoclonal Antibodies

• Purified Proteins

  • Leukemia Inhibitory Factor (LIF)

  • P53 Protein

  • P38 Protein

  • Other Purified Proteins

• Recombinant Proteins

• • Serum Albumin

  • Amyloid Protein

  • Defensin

  • Transferrin

• Vaccines

• • Recombinant Vaccines

  • Conventional Vaccines

  • Recombinant Enzymes

• Recombinant Growth Factors

• • Erythropoietin

  • Granulocyte Colony Stimulating Factors

• Recombinant Hormones

• • Recombinant Human Growth Hormones

  • Recombinant Insulin

  • Other Recombinant Hormones

• Other Product Types

By Therapeutic Application

• Oncology

• Inflammatory and Infectious Diseases

• Neurological Diseases

• Infectious Diseases

• Cardiovascular Diseases

• Metabolic Disorders

• Hormonal Disorders

• Other Diseases

Purchase this report (Price 2999 USD for a Single-User License) –https://www.reportcrux.com/buyNow/Biopharma-Market

The report highlights in-depth quantitative as well as qualitative insights, historical data, and market size projections till 2027. It also gives a perspective on manufacturers, associations, specific organizations, industries, companies, and suppliers that work to expand their business worldwide. Value chain analysis of the industry is explained in detail this providing a clear view of key mediators involved. The report studies the global Biopharma market size from the company, major regions and countries, products type, end users and applications, background information, and also predictions to 2027.

In depth competitive landscaping, recent developments by competitors and product pipelines are covered in the report. Further, the report focuses on various strategies adopted by different key stakeholders with respect to product marketing. The consumption or sales revenue, consumption market share and its growth across the applicable regions is described in detail in the report. In addition, it also studies the sales channels and strategies that are adopted by different leading manufacturers.

Contact Us:

Name: Mr. Scott Mody

Email:sales@reportcrux.com

Website: https://www.reportcrux.com/

Phone: +1-888-526-5515 (US/Canada), +91 89561 57215 (India)